All news

Truist starts PTC Therapeutics at hold, $62 target

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

Truist Financial initiated coverage on PTC Therapeutics (NASDAQ:PTCT) with a hold rating and a $62 price target, well below the $95.07 average analyst target and the broader Moderate Buy consensus. The biopharmaceutical company recently beat consensus estimates with $0.92 EPS and $360.52 million in revenue, up 101.5% year over year.

Read original source

PTCT company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.